How Mounjaro Works: the dual-receptor science behind tirzepatide

What are GIP and GLP-1, and why does activating both matter?

Your gut releases two hormones after a meal: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both signal to the pancreas to release insulin in response to food. Both also communicate with areas of the brain involved in hunger and satiety. Most weight-loss injections available in the UK act on GLP-1 alone. Tirzepatide (the active molecule in Mounjaro) is designed to bind to both receptors, and that combination appears to produce effects greater than either pathway could achieve on its own.

GIP receptors are found not just in the pancreas but in fat tissue, where they may influence how the body stores and processes fat. GLP-1 receptors are concentrated in the gut, the pancreas and the brain's appetite centres. By engaging both, tirzepatide affects satiety from multiple angles at once, and if you want a deeper look at the physiological picture, the page covering how Mounjaro works goes further into those tissue-level effects.

The NHS describes tirzepatide as working by slowing gastric emptying and reducing appetite, and the NHS medicines page for tirzepatide is a useful plain-English reference for anyone starting treatment. Eli Lilly manufactures Mounjaro; it carries a Black Triangle (▼) on its UK licence, meaning the MHRA actively collects post-market safety data on it.

What does tirzepatide actually do once it reaches your system?

After a weekly subcutaneous injection, tirzepatide circulates and begins binding to GIP and GLP-1 receptors across several organ systems. The most noticeable early effect for most people is reduced hunger. Meals feel satisfying sooner, the urge to snack between them lessens, and overall calorie intake falls, not through willpower but through a genuine shift in appetite signalling.

Gastric emptying slows, so food moves from the stomach to the small intestine more gradually. That steadier absorption also helps keep blood-glucose levels more stable after eating, which is part of why tirzepatide is also licensed for type 2 diabetes management. The stabilisation of blood sugar matters for weight management too: sharp spikes and crashes can drive hunger, so flattening that curve tends to help.

The starting dose of 2.5 mg exists precisely because these effects need time to be introduced gently. The body adjusts over several weeks, and nausea (the most common early side effect) tends to settle as the system acclimates. A prescriber titrates the dose upward from there, typically in four-week steps, based on how treatment is going. For a fuller account of the way Mounjaro works for weight loss, readers will find the clinical evidence covered in detail there.

Side effects are mostly gastrointestinal in the early weeks: nausea, constipation, indigestion and loose stools are the most frequently reported. They generally ease as the dose stabilises. Rare but serious signs (severe stomach pain that radiates to the back, signs of an allergic reaction, or sudden vision changes) need prompt medical attention. You can report any suspected side effect to the MHRA via the Yellow Card scheme.

How does tirzepatide's mechanism compare to how other weight-loss medicines work?

GLP-1 receptor agonists like semaglutide (the active ingredient in Wegovy) work along a single signalling pathway. Tirzepatide's additional GIP activity is thought to be the reason head-to-head evidence shows greater average weight reduction with Mounjaro, and anyone curious about the science behind that difference can find a detailed explanation on the page about how the Mounjaro jab works, which unpacks the mechanism clearly. In the SURMOUNT-5 open-label trial, published in the New England Journal of Medicine in 2025, participants on tirzepatide lost significantly more weight on average over 72 weeks than those on semaglutide 2.4 mg.

That does not make tirzepatide the right choice for every person, clinical history, existing conditions, medication interactions and tolerance all feed into which treatment a prescriber recommends. The alternatives to Mounjaro page sets out the comparison honestly. Cost is also part of the practical picture; the Mounjaro price comparison page explains what UK private treatment typically costs and what any legitimate price should include.

One detail worth knowing: because tirzepatide can reduce the absorption of oral medications taken around the same time, women using oral contraceptives are advised to add a barrier method for the first four weeks of treatment and for four weeks after each dose increase. That is an easy thing to overlook, and our prescribers flag it during the consultation as standard.

Does the mechanism explain why results take time to show?

Yes, and understanding this often prevents unnecessary frustration early in treatment. The receptor-binding effects are present from the first dose, but appetite regulation is a gradual recalibration rather than an on/off switch. Full titration to the maintenance dose can take several months. Clinical trials run for 68 to 72 weeks for a reason: meaningful, sustained weight loss requires the body to adapt at a hormonal level, and that process is not linear.

Weight loss tends to accelerate as the dose increases, then plateau as the body reaches a new set-point. Staying active and maintaining protein intake during treatment helps preserve muscle mass alongside fat loss, something the weight-loss treatments overview discusses in the context of what works alongside medication. Our prescribers at nume review your progress before every repeat order, not just at sign-up, so any concerns about how treatment is progressing can be discussed at each stage.

If you are trying to plan around timing (a holiday, a busy period at work, the weeks around payday) our team can advise on what to do if a dose window shifts. The consultation is the right place to raise that. You can start your free consultation today; a GPhC-registered prescriber reads every submission the same day it arrives.